NASDAQ : BFRG

Bullfrog AI Holdings, Inc. Common Stock — News

$0.607 USD

$0.03 (4.66%)

Volume
74.12K
Average Volume
237.15K
Market Capitalization
$11.25M
P/E Ratio
-1.10
Dividend Yield
0.00%
Price Target
Year High
$2.04
Year Low
$0.43
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$8.15
Source Headline
BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference

GAITHERSBURG, Md., July 22, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), an AI company using three complementary capabilities to turn complex biomedical data into actionable insights, announces that the Company's management team will participate in the BTIG Virtual Biotechnology Conference being held on July 28-29, 2026.

globenewswire.com - 2026-07-22 16:15:00

BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026

GAITHERSBURG, Md., July 21, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), an AI company using three complementary capabilities to turn complex biomedical data into actionable insights, announces that Vin Singh, Founder and Chief Executive Officer of BullFrog AI, will participate in the upcoming Water Tower Research Fireside Chat Series, taking place on Thursday, July 23, 2026 at 1:00 pm ET.

globenewswire.com - 2026-07-21 16:15:00

Water Tower Research Publishes Initiation of Coverage Report on BullFrog AI Holdings, Inc., "Helping Big Pharma Look Before It Leaps in Drug Discovery"

June 24, 2026, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on BullFrog AI Holdings, Inc. (NASDAQ: BFRG) titled, “Helping Big Pharma Look Before It Leaps in Drug Discovery”. The report can be accessed here. BullFrog AI Holdings, Inc. (NASDAQ: BFRG) is a Gaithersburg, Maryland-based AI company that is focused on the pharmaceutical R&D market. BullFrog uses AI to increase the success rate of drug development while reducing the time and investment it requires. The company commercializes a proprietary, end-to-end AI and ML platform that prepares biomedical data, identifies the biological drivers of disease, and supports development decisions. The platform targets a core inefficiency in drug development: bringing a new drug to market typically takes 10-15 years and $1-2 billion, and even then, roughly half of the drugs that reach Phase 3 still fail, often because developers picked the wrong target or could not identify which patients a drug actually helps.

thenewswire.com - 2026-06-24 13:00:00

BullFrog AI Announces New Commercial Leadership Team to Execute Growth Strategy for its Integrated Pharma AI Platform

GAITHERSBURG, Md., June 02, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, today announced it has appointed commercial technology sales and scientific-focused leaders to support the momentum of the Company's commercial business driven growth strategy.

globenewswire.com - 2026-06-02 08:00:00

Get BFRG Insider Trade Alerts

BFRG Price Target Summary

Last Month

0 analysts

Last Quarter

0 analysts

Last Year

0 analysts

All Time

0 analysts

BFRG Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade